A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area

Table 5 Protective efficacy (and confidence interval) for mefloquine and tafenoquine for malaria prophylaxis in non-immune Australian soldiers deployed to Timor Leste for six months in 2000/2001 (an attack rate of 7.88% was assumed)

	Results during the prophylactic phase of Study 033	Protective efficacy (PE) during prophylactic phase of Study 033
Drug	ITT Population	Malaria cases	Subjects lost to follow-up	Drug attack rate (%) (95% CI)*	PE (%)**	95% CI***
Mefloquine	161	0	0	0 (0, 0.549)	100	79 - 100
Tafenoquine	490	0	0	0 (0, 1.653)	100	93 – 100

*Confidence interval (CI) for the attack rate (AR) is based on Wilson (score) method for proportions. In the special case when AR = 0 (0/n), the upper limit corresponds to a one-sided upper 95% limit. For AR = 0, the lower limit is set to zero.
**PE = [1 – drug AR/0.0788)]100. For zero cases, PE = 100%.
***95% CI for protective efficacy (PE) obtained from corresponding limits for the drug attack rates. The lower limit for PE = [1- AR upper limit/0.0788] x 100. The upper AR limits for tafenoquine (0/490) and mefloquine (0/161) are 0.549% and 1.653%. For PE = 100%, the upper limit is set to 100%.

ISSN: 1475-2875